Rigel Pharmaceuticals RIGL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's accrued expenses?
- Rigel Pharmaceuticals (RIGL) reported accrued expenses of $6.01M in Q1 2026.
- How has Rigel Pharmaceuticals's accrued expenses changed year-over-year?
- Rigel Pharmaceuticals's accrued expenses decreased by 0.2% year-over-year, from $6.02M to $6.01M.
- What is the long-term trend for Rigel Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accrued expenses has grown at a 4.4% compound annual growth rate (CAGR), from $9.59M to $11.91M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.